Roche Tests Arthritis Drug Actemra for COVID-19 Pneumonia

Through its Genentech unit, Roche (OTC: RHHBY) is testing its rheumatoid arthritis drug Actemra as a potential treatment for pneumonia in patients with COVID-19, the disease caused by the new coronavirus. Roche said the Food and Drug Administration approved the start of the company's COVACTA phase 3 clinical trial.